Progress in the Total Synthesis of Several Goji Berry-Pyrrole Alkaloids by Rague, Andrea
  
 
 
 
 
 
 
 
 
 
Progress in the Total Synthesis of Several Goji Berry-Pyrrole Alkaloids 
 
 
Research Thesis 
 
 
Presented in partial fulfillment of the requirements for graduation with research distinction in 
Chemistry in the undergraduate colleges of The Ohio State University 
 
by 
 
Andrea L. Rague 
 
 
The Ohio State University 
April 15, 2016 
 
Project Advisor: Dr. A. Douglas Kinghorn, College of Pharmacy, Department of Medicinal 
Chemistry and Pharmacognosy 
ii 
 
Abstract 
Goji berries, the fruits of Lycium barbarum L. (Solanaceae), have become increasingly 
popular in the U.S. as a “super fruit” and botanical dietary supplement. Goji berry extracts have 
demonstrated numerous biological effects including immunomodulatory, anti-aging, and anti-
cancer activities. Several amino acid-containing pyrrole alkaloids isolated from these extracts 
have shown potency in a quinone reductase induction assay, suggesting potential 
chemopreventive activity. These isolates possess similar structures, but it remains unclear what 
causes one to be more active than another. While it is known that each compound contains a 
chiral center, it is unknown what the configuration of each is. The purpose of this project was to 
investigate potential synthetic schemes that can be used for the total synthesis of each of the five 
isolated pyrrole alkaloids. The total synthesis of these compounds will allow for the 
determination of the stereochemical descriptors for each isolated molecule. This synthesis will be 
performed through the Paal-Knorr pyrrole synthesis method, which combines a saturated 1,4-
diketo compound and a primary amine to form a pyrrole. The synthesized compounds will have a 
known stereochemistry and by comparing their optical rotation and circular dichroism with those 
obtained for the isolated compounds, the stereochemical descriptors can be determined. 
Additionally, this synthetic method will enable the interrogation of the structure activity 
relationship of these compounds by synthesizing both their R and S isomers, as well as novel 
pyrroles using additional amino acids. Several synthetic schemes have been tested in attempts to 
synthesize the desired pyrroles. Further studies are also being conducted which involve the use 
of the Maillard Reaction instead of the Paal-Knorr Pyrrole Synthesis as a method for forming the 
isolated pyrrole alkaloids. 
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1.1 Dietary Supplements 
 
Botanical dietary supplements have become increasingly popular over the past decade. In 
2002, 18.8% of U.S. adults reported using at least one kind of herbal or botanical dietary 
supplement within the past week.
1
 A recent survey of dietary supplement use revealed that 
roughly 68% of adults are now using dietary supplements and 31% use herbal and botanical 
dietary supplements.
2
 Of these botanicals, green tea, cranberry, garlic, ginseng, Echinacea, 
Ginkgo biloba, turmeric, and milk thistle are some of the most popular.
3
 In the U.S. more than 
55,000 dietary supplement products are currently on the market and 30% of global dietary 
supplement sales are represented.
4
 
The Dietary Supplements Health and Education Act of 1994 (DSHEA) was enacted in 
order to establish regulations for dietary supplements that had been previously overlooked in the 
Federal Food, Drug, and Cosmetic Act of 1938.
5
 This act defines the term “dietary supplement” 
and lists what a dietary supplement may contain, what it is intended for, what it may do, and 
what it will not include.
5
 Additionally, it lists the potential hazards of dietary supplements and 
provides regulations for the labeling of these products.
5
 The global market for dietary 
supplements has increased significantly since the initiation of DSHEA. In 1994, the global 
nutrition and supplements market was only $4 billion per year, but rose to $32 billion in 2012.
6–8
 
 With the increasing popularity of botanical dietary supplements, the international market 
for herbal products has also increased, especially in countries such as India, Japan, and China, 
where traditional herbal medicine has been used for centuries. In the U.S. botanical dietary 
supplements are commonly sold as fresh plant products, dried botanical powders, botanical 
extracts (liquid or dried), and purified natural compounds.
9
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 Epidemiological studies have indicated a correlation between increased consumption of 
fruits and vegetables and a decreased risk for diseases such as hypertension, coronary heart 
disease, stroke, and various forms of cancer.
10
 In recent years, further studies have shown the 
effectiveness of berries such as raspberries, strawberries, blueberries, noni, acai and goji berries 
in inhibiting tumor progression in vivo.
11
 While some of these berries are already sold as 
botanical dietary supplements, purification and synthesis of the active compounds in these fruits 
could lead to more effective dietary supplements.  
 
1.2 Goji Berries 
 
 Goji berries, or wolfberries, are the fruits of Lycium barbarum (Solanaceae). These fruits 
have been used in East Asia as both food and a traditional medicine for centuries. Goji berries 
have become increasingly popular in North America as a health food and dietary supplement. 
The fruits are commonly sold in the U.S. as a dried fruit, but can be eaten fresh as well. In 
traditional medicine, goji berries have been used to cure abdominal pain, dry coughs, fatigue, and 
headaches, as well as increase longevity and stop prematurely grey hair.
12
  
 The berries have been studied for their many health benefits, but research has focused on 
the antioxidant and immunomodulatory activities related to diseases such as atherosclerosis, 
neurodegeneration and diabetes.
13
 In recent literature their chemopreventive activity was also 
studied, and the berries were shown to be effective in inhibiting N-nitrosomethylbenzylamine 
(NMBA)-induced tumorigenesis in the rat esophagus.
11
 Additionally, studies have been done on 
the extracts of goji berries. The extracts of the fruits contain polysaccharides, carotenoids, 
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flavonoids, several vitamins, and free amino acids, as well as several other compounds with 
varying bioactivities.
12
 
  
Figure 1.1 Target compounds isolated from Goji berries 
 The previous bioassay-guided fractionation of a goji berry-extracts has led to the isolation 
and characterization of several novel compounds that have shown activity in vitro with the 
quinone reductase-induction assay.
14
 Of the active compounds, five (1-5) are pyrrole alkaloids 
with N-alkyl amino acid side chains (Figure 1.1).
14,15
 Owing to the in vitro activity and their 
structural similarity, development of a method to synthesize these compounds would allow for 
further in vitro testing as well as possible in vivo studies. Additionally, the development of a 
convergent synthesis method would allow for a quantitative study of the structure-activity 
relationship between D and L isomers as well as pyrrole alkaloids with different N-alkyl side 
chains.  
 
1.3 Paal-Knorr Pyrrole Synthesis 
 
 Five-membered heterocycles are found throughout Nature, especially in many 
biologically active small-molecule natural product compounds.
14
 Therefore, the ability to 
synthesize pyrroles, furans and thiophenes is incredibly valuable in synthetic medicinal 
chemistry. The Paal-Knorr furan synthesis was first reported in 1884 as an acid-catalyzed 
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cyclization of 1,4-diketones to form furans.
16–18
 This method was later modified for the synthesis 
of both thiophenes and pyrroles.
19
  
 The mechanism for this reaction (Figure 1.2) was elucidated in 1991 by V. Amarnath et. 
al.
20
 In this reaction, the nitrogen of a primary amine bonds with one of the carbonyl carbons.  
Figure 1.2 Paal-Knorr Pyrrole Synthesis mechanism 
The oxygen is then protonated and the nitrogen bonds with the remaining carbonyl carbon and 
the oxygen is again protonated. The removal of water leads to the desired pyrrole compound. 
Additionally, V. Amarnath confirmed that the rate of reaction is affected adversely by the size of 
the alkyl substituents on the dione.
20
 This reaction was used as the crux for the synthesis of the 
isolated pyrrole alkaloids, because the amino acids could potentially be used as the primary 
amine if a suitable 1,4-diketone compound could be synthesized as a precursor.  
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2.1 Synthetic Approach 
 
The limited amount of each pyrrole isolated earlier from Goji berries precluded any 
further biological testing on the compounds.
14
 In order to do further biological testing, determine 
the stereochemistry, and to conduct quantitative structure-activity relationship studies, it was 
considered that a method must be developed to synthesize these molecules.  
 
Figure 2.1 Retrosynthetic analysis of general pyrrole compound 
The initial synthetic scheme was developed using a retrosynthetic approach (Figure 2.1). 
The Paal-Knorr pyrrole synthesis was used as the starting point for this retrosynthesis, and 5-
hydroxymethylfurfural was considered as a possible starting material. Pyrrole A could be formed 
with an acid-catalyzed Paal-Knorr synthesis, using the saturated 1,4-diketone B as a starting 
material. Compound B could be formed by reducing the C-2:C-3 unsaturated bond in diketone C. 
An oxidative ring opening could be used to form saturated diketone C from the furan, D. From D 
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the protecting group R2 would be removed, the primary alcohol would be converted to an 
aldehyde, and R1 would be removed to form E, F, and G, respectively.  
 
Figure 2.2 General synthetic scheme 
From this retrosynthetic scheme, a potential synthetic method was developed (Figure 
2.2). Starting with 5-hydroxymethylfurfural I, the first protecting group was installed on the C-5 
side chain. In all of the proposed variations of this scheme, a tetrahydropyranyl (THP) ether 
protecting group was installed first.
21
 Next, the aldehyde on the C2 chain is reduced to a primary 
alcohol in order to install the second protecting group. This reaction is done using a sodium 
borohydride reduction in methanol.
22
 The second protecting group is then installed on the C2 side 
chain. This protecting group was first selected to be a tert-butyldiphenylsilyl (TBPS) ether,
23
 but 
a triethylsilyl (TES) ether,
22
 acetate (Ac) ester,
24
 and benzyl (Bn) ether
25–27
 were also installed in 
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different trials to form IV. The furan was oxidized with anhydrous meta-chloroperozybenzoic 
acid (MCPBA) to form the unsaturated 1,4-diketone V.
28,29
 The C-2:C-3 unsaturated bond was 
then reduced using zinc powder in acetic acid to form VI.
28,29
 This unsaturated diketone was 
used as the precursor for the Paal-Knorr pyrrole synthesis with a methoxy amino acid as the R3 
group.
28,30,31
 Upon successful synthesis of VII, R2 would be removed to form VIII, and the 
primary alcohol would be partially oxidized to aldehyde IX. The second protecting group, R1, 
would then be cleaved to form X. Finally, the primary alcohol would be converted to a methoxy 
group to form the desired pyrrole compound. 
 
2.2 The Use of tert-Butyldiphenylsilyl Ether as the R2 Group 
 
Figure 2.3 Synthetic scheme using TBDPS protecting group 
The first attempts at synthesis involved the use of the tetrahydropyranyl ether (THPO) as R1 and 
the tert-butyldiphenylsilyl ether (TBDPSO) as R2 (Figure 2.3). The THPO protecting group is 
installed under acidic conditions, it is stable under the proposed reaction conditions, and is 
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removed by acid hydrolysis using p-toluenesulfonic acid in methanol.
32,33
 Silyl ethers such as 
TBDPSO can be removed with tetra-n-butylammonium fluoride (TBAF).
32,34,35
 Both protecting 
groups were stable under the oxidation of the furan and the reduction of the unsaturated bond; 
however, the Paal-Knorr pyrrole synthesis was unsuccessful. Each attempt resulted in recovery 
of at least 50% of the starting material and none of the desired pyrrole.  
 
Figure 2.4 Structure of the TBDPS saturated diketone (carbonyl carbons in yellow) 
It is possible that the bulky TBDPSO group causes steric hindrance, which prevents the 
formation of C-N bonds during the attempted pyrrole synthesis. The bulky nature of 6a is 
presented in Figure 2.4. It is likely that the nitrogen of the amino acid is unable to position itself 
to bond with either of the carbonyl carbons.  
 
2.3 The Use of Triethylsilyl Ether as the R2 Group 
 
The next synthetic method (Figure 2.5) involved the use of the triethylsilyl ether (TESO) 
protecting group. This group is stable under many of the same reaction conditions as TBDPSO, 
11 
 
but is significantly smaller than the TBDPSO group. Use of this group in the Paal-Knorr pyrrole 
synthesis could remove the steric hindrances that may prevent the reaction from taking place. 
The TES protecting group was successfully installed, but when MCPBA was used for the 
oxidative cleavage of the furan ring, none of the desired diketone was synthesized.  
 
Figure 2.5 Synthetic scheme using the TES protecting group 
When the products were separated using column chromatography, small amounts of 3 were 
recovered, along with the cleaved TES group, but none of the diketone was collected. Since 
TESO is not as stable in acidic conditions, it is likely that the mildly acidic MCPBA prevents the 
protecting group from staying intact.  
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2.4 Removal of TBDPS 
Figure 2.6 Synthetic scheme cleaving TBDPS protecting group from the saturated diketone 
While the TESO group is not stable under the acidic/oxidation conditions, it is possible that that 
it would still be stable under the reaction conditions for the pyrrole synthesis. The next synthetic 
method that was attempted (Figure 2.6) involved combining the use of the TES and TBDPS 
ethers. The TBDPS ether would be used through the oxidation of the furan, and then replaced 
with TES for the pyrrole synthesis. The unsaturated diketone 6a was treated with TBAF in order 
to remove the TBDPS. However, the reaction was unsuccessful under these conditions.  
 
Figure 2.7 Synthetic scheme cleaving TBDPS protecting group from the unsaturated 
diketone 
13 
 
Next, the unsaturated diketone 5a was treated with TBAF to remove the TBDPS at an earlier 
step, but there was no reaction (Figure 2.7). The increasing size of silyl ether protecting groups 
leads to an increase in resistance to both protection and deprotection.
36
 While the TBDPS 
protecting group is stable under many reaction conditions, it is possible that the TBDPSO 
diketone is too resistant to hydrolysis.  
 
2.5 The Use of Acetate Ester as the R2 Group 
 
Figure 2.8 Synthetic scheme using the acetate ester protecting group 
The third protecting group that was used in the original scheme (Figure 2.8) was the acetate ester 
(AcO). It is small like the TESO protecting group, but is also stable under highly acidic 
conditions. This protecting group is installed using acetic anhydride and triethyl amine in 
CH2Cl2. The installation of the acetate ether protecting group was successful, but when treated 
with MCPBA, there was no reaction.  
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2.6 The Use of Benzyl Ether as the R2 Group 
 
Figure 2.9 Synthetic scheme using the benzyl ether protecting group 
The final protecting group used was the benzyl ether (BnO). This protecting group is smaller 
than TBDPSO, but still stable under many reaction conditions. The protecting group is attached 
under basic conditions with benzyl bromide and is removed with H2 and palladium (Figure 
2.9).
33,34
 The BnO group was installed successfully, but was cleaved during the MCPBA 
oxidation.  
15 
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3.1 The Maillard Reaction 
 
While none of the attempts to synthesize the desired pyrrole alkaloids were completely 
successful, efforts are still being made in the synthesis of the desired compounds. One direction 
for this synthesis would involve a new synthetic scheme that begins with a Maillard Reaction. 
The Maillard Reaction, also known as “The Browning Reaction”, is a reaction that occurs 
between amino acids and sugars such as glucose and xylose, which results in a variety of 
branched, heterocyclic compounds. There have been several reports of the use of glucose and 
amino acids to produce pyrroles similar to the target compounds in yields as high as 20%.
37–39
 
While this is a low yield, both of the starting materials are inexpensive. Therefore, development 
of a new scheme that begins with a Maillard Reaction may result in the synthesis of the desired 
pyrrole alkaloids in fewer steps and at a much lower cost.  
 
3.2 Biological and Stereochemical Interrogations 
 
Once a method for synthesizing these pyrrole alkaloids is developed, further biological, 
stereochemical, and structure-activity interrogations can be performed. The synthesized 
compounds will have a known stereochemistry and by comparing their optical rotation and 
circular dichroism with those obtained for the isolated compounds, the stereochemical 
descriptors can be determined. After the stereochemistry of each isolate is determined, the next 
step will be to synthesize the remaining isomers. Once these compounds are obtained, the 
synthesis of novel pyrrole-alkaloids will be performed using additional amino acids. The 
17 
 
structure activity relationship will be investigated by comparing the biological activities of the 
isolated compounds and their synthetic derivatives. 
Each compound synthesized will be biologically tested in order to determine their activity 
as potential chemopreventive agents. These compounds can be tested in vitro using the quinone 
reductase induction assay. The phase II enzyme NAD(P)H:quinone reductase can deactivate 
reactive species, such as radicals and electrophiles, that may disrupt normal cellular processes, 
and initiate carcinogenesis.
40
 Compounds that prove to be active in this bioassay may then be 
tested further in vivo using the methods described in 2010 by G.D. Stoner et. al.
11
 Any resulting 
leads could potentially be used to develop new cancer chemopreventive agents.  
18 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Experimental 
19 
 
 
5-(((Tetrahydro-2H-pyran-2-yl)oxy)methyl)furan-2-carbaldehyde (2). To a solution of 5-
(hydroxymethyl)furfural (3.650 g, 28.96 mmol) in CH2Cl2 (60 mL) were added 3,4-dihydro-2H-
pyran (3.17 mL, 34.7 mmol) and pyridinium p-toluenesulfonate (0.731 g, 2.91 mmol). The 
reaction mixture was stirred at room temperature for 2 h, then quenched with saturated NaHCO3 
and extracted with CH2Cl2. The organic layer was then washed with brine (3 x 100 mL), dried 
with MgSO4 and filtered. The filtrate was then concentrated in vacuo to yield compound 2 (5.793 
g, 57.84 mL, 95%) as a pale yellow oil. 
1
H NMR (300 MHz, CDCl3):  9.55 (s, 1H), 7.16 (d, 
1H), 6.47 (d, 1H), 4.66 (d, 2H), 4.52 (d, 1H), 3.81 (t, 1H), 3.51 (d, 1H), 1.67 (m, 6H). 
 
(5-(((Tetrahydro-2H-pyran-2-yl)oxy)methyl)furan-2-yl)methanol (3). A solution of 
compound 2 (5.793 g, 27.55 mmol) in methanol (110 mL) was cooled to -10°C, then NaBH4 
(1.043 g, 25.55 mmol) was added, and the reaction mixture was stirred for 2 h at 0°C. After the 
reaction mixture was concentrated in vacuo, dissolved in CH2Cl2, washed with saturated 
NaHCO3 (3 x 100 mL) and brine (3 x 100 mL), then the organic layer was dried with MgSO4 and 
filtered. The filtrate was then concentrated in vacuo to yield compound 3 (5.695 g, 26.83 mmol, 
97%) as a gold colored oil. 
1
H NMR (300 MHz, CDCl3):  6.15 (d, 2H), 4.62 (s, 1H), 4.53 (d, 
1H), 4.44 (s, 2H), 4.35 (d, 1H), 3.79 (t, 1H), 3.46 (t, 1H), 1.60 (m, 6H). 
20 
 
 
tert-Butyldiphenyl((5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)furan-2-yl)methoxy)silane 
(4a). To a solution of compound 3 (2.448 g, 11.53 mmol) in CH2Cl2 (65 mL), were added 
triethylamine (3.34 mL, 23.96 mmol), DMAP (0.145 g, 1.186 mmol), and TBDPSCl (3.71 mL, 
14.26 mmol). After stirring at room temperature for 12 h, the solution was quenched with water 
(20 mL) and extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were then washed 
with saturated NaHCO3 (3 x 100 mL) and brine (3 x 100 mL), then dried over anhydrous MgSO4 
and filtered. The filtrate was then concentrated in vacuo to yield compound 4a (5.025 g, 10.72 
mmol, 95%) as a yellow oil. 
1
H NMR (300 MHz, CDCl3):  7.72 (m, 4H), 7.40 (m, 6H), 6.25 (t, 
1H), 6.12 (t, 1H), 4.67 (m, 4H), 4.47 (m, 1H), 3.93 (m, 1H), 3.56 (m, 1H), 1.65 (m, 6H), 1.10 (s, 
9H). 
 
 
(Z)-1-((tert-Butyldiphenylsilyl)oxy)-6-((tetrahydro-2H-pyran-2-yl)oxy)hex-3-ene-2,5-dione 
(5a). To a solution of compound 4 (5.277 g, 11.71 mmol) in anhydrous CH2Cl2 (40 mL) was 
added purified MCPBA (3.818 g, 22.12 mmol). The reaction mixture was stirred at room 
temperature, under argon gas, for 4 h, then filtered through a silica gel pad. The mixture was then 
washed with saturated NaHCO3 (3 x 100 mL) and brine (3 x 100 mL), and then dried with 
anhydrous Na2SO4 and filtered. The filtrate was then concentrated in vacuo to yield compound 
5a (2.734 g, 5.859 mmol, 50%) as a pale yellow oil.
 1
H NMR (300 MHz, CDCl3):  7.71 (m, 
4H), 7.45 (m, 6H), 6.26 (d, 1H), 6.14 (d, 1H), 5.57 (s, 2H), 5.49 (q, 2H), 4.97 (s, 1H), 3.84 (t, 
1H), 3.56 (t, 1H), 1.64 (m, 6H), 1.11 (s, 9H). 
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1-((tert-Butyldiphenylsilyl)oxy)-6-((tetrahydro-2H-pyran-2-yl)oxy)hexane-2,5-dione (6a). To 
a solution of compound 5a (0.255 g, 0.546 mmol) in acetic acid (5.46 mL) was added zinc 
powder (0.179 g, 2.74 mmol). The reaction was stirred at room temperature for 2 h, the zinc cake 
was filtered and washed with CH2Cl2. The filtrates were washed with saturated NaHCO3 (3 x 
100 mL) and brine (3 x 100 mL), then dried over anhydrous Na2SO4 and filtered. The filtrate was 
then concentrated in vacuo to yield compound 6a (0.1809 g, 0.389 mmol, 71%) as a pale yellow 
oil. 
1
H NMR (300 MHz, CDCl3):  7.71 (m, 4H), 7.45 (m, 6H), 5.47 (s, 2H), 5.41 (s, 2H), 4.94 
(t, 1H), 5.49 (q, 2H), 3.84 (m, 1H), 3.56 (m, 1H), 2.56 (m, 4H), 1.64 (m, 6H), 1.11 (s, 9H). 
 
 
D-Methyl 2-aminopropanoate. A solution of D-alanine (0.497 g, 5.58 mmol) in methanol (5 
mL) was stirred at -10°C, then SOCl2 (0.59 mL, 8.2 mmol) was added dropwise over 10 min. 
The reaction mixture was stirred at room temperature for 2 h, then under reflux overnight. The 
volatiles were then concentrated in vacuo to yield D-methyl 2-aminopropanoate (0.575 g, 5.58 
mmol, 100%) as an off-white solid, which was used without further purification. 
1
H NMR (300 
MHz, CDCl3):  4.27 (s, 1H), 3.81 (s, 3H), 2.42 (s, 2H), 1.72 (d, 3H). 
22 
 
 
(2S)-Methyl2-(2-(((tert-butyldiphenylsilyl)oxy)methyl)-5-(((tetrahydro-2H-pyran-2-
yl)oxy)methyl)-1H-pyrrol-1-yl)propanoate (7a). 
Method A: A solution of D-methyl 2-aminopropanoate (13.7 mg, 0.133 mmol) and triethylamine 
(0.019 mL, 0.13 mmol) in THF (0.16 mL) was stirred at room temperature for 20 min. To the 
solution were added compound 6a (74 mg, 0.16 mmol) and iodine (34 mg, 0.27 mmol). The 
reaction was stirred for 24 h at room temperature, then CH2Cl2 (25 mL) was added and the 
mixture was washed with 0.1 M Na2S2O3 (3 x 10 mL) and 0.5 M NaHCO3 (3 x 10 mL), then 
dried over anhydrous Na2SO4 and filtered. The filtrate was then concentrated in vacuo but 
compound 7a was not formed.  
 
Method B: A solution of D-methyl 2-aminopropanoate (7.4 mg, 0.072 mmol) and triethylamine 
(0.010 mL, 0.07 mmol) in THF (0.09 mL) was stirred at room temperature for 20 min. To the 
solution were added compound 6a (40 mg, 0.085 mmol) and iodine (1.8 mg, 0.14 mmol). The 
reaction was stirred for 72 h at room temperature, then CH2Cl2 (25 mL) was added and the 
mixture was washed with 0.1 M Na2S2O3 (3 x 10 mL) and 0.5 M NaHCO3 (3 x 10 mL), then 
dried over anhydrous Na2SO4 and filtered. The filtrate was then concentrated in vacuo but 
compound 7a was not formed. 
 
Method C: A solution of D-methyl 2-aminopropanoate (8.2 mg, 0.080 mmol) and triethylamine 
(0.011 mL, 0.079 mmol) in CH2Cl2 was stirred at room temperature for 20 min. To the solution 
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were added compound 6a (40.5 mg, 0.096 mmol) and AcOH (0.023 mL, 0.40 mmol). The 
reaction was stirred for 72 h at room temperature then CH2Cl2 (25 mL) was added and the 
mixture was washed with 0.1 M Na2S2O3 (3 x 10 mL) and 0.5 M NaHCO3 (3 x 10 mL), then 
dried over anhydrous Na2SO4 and filtered. The filtrate was then concentrated in vacuo but 
compound 7a was not formed. 
 
Method D: To a solution of D-methyl 2-aminopropanoate (8.8 mg, 0.086 mmol) in THF (0.0865 
mL) were added compound 6a (45.2 mg, 0.096 mmol) and iodine (2.2 mg, 0.017 mmol). The 
reaction was stirred for 12 h at room temperature, then CH2Cl2 (25 mL) was added and the 
mixture was washed with 0.1 M Na2S2O3 (3 x 10 mL) and 0.5 M NaHCO3 (3 x 10 mL), then 
dried over anhydrous Na2SO4 and filtered. The filtrate was then concentrated in vacuo but 
compound 7a was not formed. 
 
Method E: To a solution of D-methyl 2-aminopropanoate (10.8 mg, 0.11 mmol) in THF (0.106 
mL) were added compound 6a (56.0 mg, 0.11 mmol) and iodine (2.7 mg, 0.021 mmol). The 
reaction was stirred under reflux overnight, then CH2Cl2 (25 mL) was added and the mixture was 
washed with 0.1 M Na2S2O3 (3 x 10 mL) and 0.5 M NaHCO3 (3 x 10 mL), then dried over 
anhydrous Na2SO4 and filtered. The filtrate was then concentrated in vacuo but compound 7a 
was not formed. 
 
Method F: To a solution of D-methyl 2-aminopropanoate (14.7 mg, 0.143 mmol) in CH2Cl2 
(0.71 mL) were added compound 6a (80.9 mg, 0.173 mmol) and AcOH (0.041 mL 0.723 mL). 
The reaction was stirred for under reflux for 4 h, then CH2Cl2 (25 mL) was added and the 
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mixture was washed with saturated NaHCO3 (3 x 10 mL) and brine (3 x 10 mL), then dried over 
anhydrous Na2SO4 and filtered. The filtrate was then concentrated in vacuo but compound 7a 
was not formed. 
 
Triethyl((5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)furan-2-yl)methoxy)silane (4b). To a 
solution of compound 3 (1.4715 g, 6.933 mmol) in CH2Cl2 (40 mL), were added triethylamine 
(1.88 mL, 13.4 mmol), DMAP (0.081 g, 0.66 mmol), and TESCl (1.35 mL, 8.04 mmol). After 
stirring at room temperature for 12 h, the solution was quenched with water (20 mL) and 
extracted with CH2Cl2. The combined organic layers were then washed with saturated NaHCO3 
(3 x 75 mL) and brine (3 x 75 mL), then dried over anhydrous MgSO4 and filtered. The filtrate 
was then concentrated in vacuo to yield compound 4b (2.128 g, 6.517 mmol, 94%) as a yellow 
oil. 
1
H NMR (300 MHz, CDCl3):  6.21 (d, 1H), 6.15 (d, 1H), 4.67 (t, 1H), 4.57 (s, 2H), 4.42 (d, 
2H), 3.66 (m, 1H), 3.50 (m, 1H), 1.59 (m, 6H), 0.92 (m, 9H), 0.60 (m, 6H). 
 
 
(Z)-1-((Triethylsilyl)oxy)-6-((tetrahydro-2H-pyran-2-yl)oxy)hex-3-ene-2,5-dione (5b). To a 
solution of compound 4b (1.8672 g, 5.72 mmol) in anhydrous CH2Cl2 (40 mL) was added 
purified MCPBA (1.8495 g, 10.71 mmol). The reaction mixture was stirred at room temperature, 
under argon gas for 4 h, then filtered through a silica gel pad. The mixture was then washed with 
saturated NaHCO3 (3 x 75 mL) and brine (3 x 75 mL), then dried over anhydrous MgSO4 and 
filtered. The filtrate was then concentrated in vacuo and loaded onto a silica gel column, but the 
product was not retrieved from the column. 
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(Z)-1-Hydroxy-6-((tetrahydro-2H-pyran-2-yl)oxy)hex-3-ene-2,5-dione (7c). A solution of 
compound 6a (0.201 g, 0.428 mmol) in THF (4.5 mL) was stirred at 0°C for 15 min, then acetic 
acid (0.1 mL, 0.52 mmol) and TBAF (1.6 mL, 1.0 M in THF, 0.0016 mmol) were added and 
stirred at room temperature for 18 h, then washed with saturated NH4Cl solution (3 x 20 mL), 
extracted with CH2Cl2, and dried over anhydrous MgSO4 and filtered. The filtrate was then 
concentrated in vacuo and loaded onto a silica gel column, but the product was not retrieved 
from the column. 
 
 
1-Hydroxy-6-((tetrahydro-2H-pyran-2-yl)oxy)hexane-2,5-dione (6c). A solution of 
compound 5a (0.177 g, 0.379 mmol) in THF (4.1 mL) was stirred at 0°C for 15 min, then acetic 
acid (0.08 mL, 1.19 mmol) and TBAF (1.1mL, 1.0 M in THF, 0.0011 mmol) were added and 
stirred at room temperature for 24 h, then washed with saturated NH4Cl solution (3 x 20 mL), 
extracted with CH2Cl2, then dried over anhydrous MgSO4 and filtered. The filtrate was then 
concentrated in vacuo and loaded onto a silica gel column, but the product was not retrieved 
from the column. 
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(5-(((Tetrahydro-2H-pyran-2-yl)oxy)methyl)furan-2-yl)methyl acetate (4d). To a solution of 
compound 3 (0.501 g, 2.36 mmol) in CH2Cl2 (150 mL) were added triethylamine (5.26 mL, 37.8 
mmol), acetic anhydride (5.13 mL, 54.3 mmol), and DMAP (0.018 g, 0.14 mmol). The reaction 
was stirred at room temperature for 2 h, and then quenched with methanol (50 mL). The mixture 
was diluted with CH2Cl2, washed with saturated NaHCO3 (3 x 150 mL), dried with anhydrous 
MgSO4, then filtered. The filtrate was then concentrated in vacuo to yield compound 4d (0.562 
g, 2.21 mmol, 94%) as a yellow colored oil. 
1
H NMR (300 MHz, CDCl3):  6.29 (d, 1H), 6.24 
(d, 2H), 4.97 (s, 2H), 4.66 (s, 1H), 4.60 (d, 1H), 4.40 (d, 1H), 3.83 (m, 1H), 3.48 (m, 1H), 2.00 
(s, 3H), 1.65 (m, 6H). 
 
 
 
(Z)-2,5-Dioxo-6-((tetrahydro-2H-pyran-2-yl)oxy)hex-3-en-1-yl acetate (5d). To a solution of 
compound 4d (0.562 g, 2.21 mmol) in anhydrous CH2Cl2 (25 mL) was added MCPBA (0.573 g, 
3.32 mmol). The reaction mixture was stirred at room temperature, under argon gas, for 4 h, and 
then filtered through a silica gel pad. The mixture was then washed with saturated NaHCO3 (3 x 
15 mL) and brine (3 x 15 mL), and then dried with anhydrous Na2SO4 and filtered. The filtrate 
was then concentrated in vacuo to yield and loaded onto a silica gel column, but the product (5d) 
did not elute from the column. 
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2-((5-((Benzyloxy)methyl)furan-2-yl)methoxy)tetrahydro-2H-pyran (4e). To a solution of 
compound 3 (0.590 g, 2.78 mmol) in acetone (5 mL) was added potassium iodide (0.092 g, 0.56 
mmol), potassium carbonate (0.576 g, 248.5 mmol), and benzyl bromide (0.36 mL, 3.1 mmol). 
The reaction was stirred at room temperature, overnight, then diluted with CH2Cl2, washed with 
saturated NaHCO3 (3 x 15 mL) and brine (3 x 15 mL), and then dried with anhydrous Na2SO4 
and filtered. The filtrate was then concentrated in vacuo to yield compound 4e (0.722 g, 2.51 
mmol, 90%) as a dark brown colored oil. 
1
H NMR (300 MHz, CDCl3):  7.27 (m, 5H), 6.26 (d, 
1H), 6.22 (d, 1H), 4.71(t, 1H), 4.63 (d, 1H), 4.54 (s, 2H), 4.45 (d, 2H), 3.88 (m, 1H), 3.53 (m, 
1H), 1.64 (m, 6H). 
  
 
(Z)-1-(Benzyloxy)-6-((tetrahydro-2H-pyran-2-yl)oxy)hex-3-ene-2,5-dione (5e). To a solution 
of compound 11 (0.512 g, 1.77 mmol) in anhydrous CH2Cl2 (20 mL) was added anhydrous 
MCPBA (0.461 g, 2.67 mmol). The reaction mixture was stirred at room temperature, under 
argon gas, for 4 hours, then filtered through a silica gel pad. The mixture was then washed with 
saturated NaHCO3 (3 x 50 mL) and brine (3 x 50 mL), and then dried with anhydrous Na2SO4 
and filtered. The filtrate was then concentrated in vacuo to yield and loaded onto a silica gel 
column, but the product did not elute from the column. 
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Appendix: NMR Spectra of Selected Compounds 
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